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dhe Role of Criterion A2 in the DSM-IV Diagnosis of
osttraumatic Stress Disorder
lie George Karam, Gavin Andrews, Evelyn Bromet, Maria Petukhova, Ayelet Meron Ruscio,
ariana Salamoun, Nancy Sampson, Dan J. Stein, Jordi Alonso, Laura Helena Andrade,
atthias Angermeyer, Koen Demyttenaere, Giovanni de Girolamo, Ron de Graaf, Silvia Florescu,
ye Gureje, Debra Kaminer, Roman Kotov, Sing Lee, Jean-Pierre Lépine, Maria Elena Medina-Mora,
ark A. Oakley Browne, José Posada-Villa, Rajesh Sagar, Arieh Y. Shalev, Tadashi Takeshima,
oma Tomov, and Ronald C. Kessler
ackground: Controversy exists about the utility of DSM-IV posttraumatic stress disorder (PTSD) criterion A2 (A2): that exposure to a
otentially traumatic experience (PTE; PTSD criterion A1) is accompanied by intense fear, helplessness, or horror.
ethods: Lifetime DSM-IV PTSD was assessed with the Composite International Diagnostic Interview in community surveys of 52,826
espondents across 21 countries in the World Mental Health Surveys.
esults: Of 28,490 representative PTEs reportedby respondents, 37.6%met criterionA2, a proportionhigher than theproportionsmeeting
ther criteria (B–F; 5.4%–9.6%). Conditional prevalence of meeting all other criteria for a diagnosis of PTSD given a PTE was significantly
igher in the presence (9.7%) than absence (.1%) of A2. However, as only 1.4% of respondents who met all other criteria failed A2, the
stimated prevalence of PTSD increased only slightly (from 3.64% to 3.69%) when A2 was not required for diagnosis. Posttraumatic stress
isorder with or without criterion A2 did not differ in persistence or predicted consequences (subsequent suicidal ideation or secondary
isorders) depending on presence-absence of A2. Furthermore, as A2 was by far the most commonly reported symptom of PTSD, initial
ssessment of A2 would be much less efficient than screening other criteria in quickly ruling out a large proportion of noncases.
onclusions: Removal of A2 from the DSM-IV criterion set would reduce the complexity of diagnosing PTSD, while not substantially
ncreasing the number of people who qualify for diagnosis. Criterion A2 should consequently be reconceptualized as a risk factor for PTSD
ather than as a diagnostic requirement.
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ontroversy exists over what should qualify as a trauma for
posttraumatic stress disorder (PTSD). Some experts favor a
broader and others a narrower definition (1,2). The DSM-IV
3) tries to find a middle ground by including both an objective
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Criterion A1 is broader than favored by some, as it includes any
event a person “experienced, witnessed, or (was) confronted with”
that involves “actual or threatened death or serious injury or a threat
to the physical integrity of oneself or others.” The inclusion of
indirect exposure and ambiguity of the term “threat to physical
integrity” are particular points of controversy (4,5). Criterion A2,
new to DSM-IV, was designed to restrict qualifying events to those
where the immediate response involved “intense fear, helplessness,
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Table 1. World Mental Health Sample Characteristics by World Bank Income Categories
Country by Income
Categorya Survey Sample Characteristicsb Field Dates
Age
Range
Sample Size
Response
RatecPart I Part II
I. High-Income
Countries
Belgium ESEMeD Stratified multistage clustered probability sample of individuals residing in households from
the national register of Belgium residents. NR
2001–2002 18 2,419 1,043 50.6
France ESEMeD Stratified multistage clustered sample of working telephone numbers merged with a reverse
directory (for listed numbers). Initial recruitment was by telephone, with
supplemental in-person recruitment in households with listed numbers. NR
2001–2002 18 2,894 1,436 45.9
Germany ESEMeD Stratified multistage clustered probability sample of individuals from community resident
registries. NR
2002–2003 18 3,555 1,323 57.8
Israel NHS Stratified multistage clustered area probability sample of individuals from a national resident
register. NR
2002–2004 21 4,859 4,859 72.6
Italy ESEMeD Stratified multistage clustered probability sample of individuals frommunicipality resident
registries. NR
2001–2002 18 4,712 1,779 71.3
Japan WMHJ 2002–2006 Unclustered two-stage probability sample of individuals residing in households in 11
metropolitan areas.
2002–2006 20 4,129 1,682 55.1
Netherlands ESEMeD Stratified multistage clustered probability sample of individuals residing in households that are
listed in municipal postal registries. NR
2002–2003 18 2,372 1,094 56.4
New Zealandd NZMHS Stratified multistage clustered area probability sample of household residents. NR 2003–2004 18 12,790 7,312 73.3
Spain ESEMeD Stratified multistage clustered area probability sample of household residents. NR 2001–2002 18 5,473 2,121 78.6
United States NCS-R Stratified multistage clustered area probability sample of household residents. NR 2002–2003 18 9,282 5,692 70.9
Total 52,485 28,341
II. Upper-Middle-Income
Countries
Brazil São Paulo
Megacity
Stratified multistage clustered area probability sample of household residents in the São Paulo
metropolitan area.
2005–2007 18 5,037 2,942 81.3
Bulgaria NSHS Stratified multistage clustered area probability sample of household residents. NR 2003–2007 18 5,318 2,233 72.0
Lebanon LEBANON Stratified multistage clustered area probability sample of household residents. NR 2002–2003 18 2,857 1,031 70.0
Mexico M-NCS Stratified multistage clustered area probability sample of household residents in all urban areas
of the country (approximately 75% of the total national population).
2001–2002 18–65 5,782 2,362 76.6
Romania RMHS Stratified multistage clustered area probability sample of household residents. NR 2005–2006 18 2,357 2,357 70.9
South Africa SASH Stratified multistage clustered area probability sample of household residents. NR 2003–2004 18 4,315 4,315 87.1
Total 25,666 15,240
III. Low-Income/Lower-
Middle-Income
Countries
Colombia NSMH Stratified multistage clustered area probability sample of household residents in all urban areas
of the country (approximately 73% of the total national population).
2003 18–65 4,426 2,381 87.7
India WMHI Stratified multistage clustered area probability sample of household residents in Pondicherry
region. NR
2003–2005 18 2,992 1,373 98.8
Nigeria NSMHW Stratified multistage clustered area probability sample of households in 21 of the 36 states in
the country, representing 57% of the national population. The surveys were conducted in
Yoruba, Igbo, Hausa, and Efik languages.
2002–2003 18 6,752 2,143 79.3
People’s Republic of
China
B-WMH
S-WMH
Stratified multistage clustered area probability sample of household residents in the Beijing
and Shanghai metropolitan areas.
2002–2003 18 5,201 1,628 74.7
Ukraine CMDPSD Stratified multistage clustered area probability sample of household residents. NR 2002 18 4,725 1,720 78.3
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E.G. Karam et al. BIOL PSYCHIATRY 2010;68:465–473 467or horror” to prevent the overdiagnosis that might otherwise occur
because of the broad scope of A1.
The few studies that focus specifically on A2 show a substan-
tial proportion of people exposed to an A1 experience—a
potentially traumatic experience (PTE)—meets A2 (4,6). This
means the A2 requirement reduces estimated prevalence only
modestly (1,7). However, failure to meet A2 strongly predicts
failure to meet other criteria (6), making assessment of A2 useful
in two ways. First, as A2 is the only PTSD criterion that can be
assessed near the time of PTE exposure, early assessment of A2
can help predict subsequent PTSD, although recent prospective
research shows that a meaningful proportion of patients who
subsequently meet all other criteria for PTSD fail to meet A2 at
the time of trauma exposure (8). Second, even when the
assessment takes place months or years after PTE exposure,
initial retrospective assessment of A2 can provide a quick
rule-out (5). At the same time, the fact that PTSD diagnoses
would increase only modestly if A2 was removed as a require-
ment argues against retaining A2 based on the interest in
simplifying diagnoses by eliminating redundant criteria (9,10).
The empiric foundation on which these competing views are
based is limited to a small number of United States and Australian
studies. Only scant data exist, furthermore, on the relationship
between A2 and other clinical correlates (4), making it unclear
whether the A2 requirement excludes clinically significant cases.
Given increasing adoption of DSM-IV criteria worldwide, it is
important to evaluate these issues using cross-national data (11).
We do this here with data from the World Health Organization
(WHO) World Mental Health (WMH) Survey Initiative (12).
Methods andMaterials
Samples
Data come from WMH surveys in 21 countries, 5 low-income
or lower-middle-income (Colombia, India, Nigeria, People’s Re-
public of China [Beijing and Shanghai], and Ukraine), 6 upper-
middle-income (Brazil, Bulgaria, Lebanon, Mexico, Romania,
and South Africa), and 10 high-income (Belgium, France, Ger-
many, Israel, Italy, Japan, Netherlands, New Zealand, Spain, and
United States) countries (Table 1). A total of 102,247 respondents
were interviewed in these surveys. Part I of the interviews, which
assessed core disorders, was completed by all respondents. Part
II assessed additional disorders, including PTSD, and correlates
and was completed by 100% of respondents who met criteria for
any part I disorder and a probability subsample of other part I
respondents. Part II sample sizes range between 1031 (Lebanon)
and 7312 (New Zealand) and total 52,826 respondents across
countries. This is the sample used here. All surveys used
multistage clustered area probability household samples repre-
sentative of specific regions (Colombia, Japan, Mexico, Nigeria,
People’s Republic of China) or entire nations (the remaining
countries). The weighted (by sample size) average response rate
was 71.6%. The part I sample was weighted to adjust for
differential probabilities of selection and residual discrepancies
between sample and census on sociodemographic and geo-
graphic variables. The part II sample was additionally weighted
to adjust for undersampling of part I respondents without part I
disorders. World Mental Health sampling and weighting are
discussed in more detail elsewhere (13).
Procedures
Respondents were interviewed face-to-face by trained layinterviewers who obtained informed consent before initiatingTa
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wnterviews. Recruitment-consent procedures were approved by
uman subjects committees in each country. Interviewer training
nd quality control procedures were cross-nationally standard-
zed (14). The instrument was the WHO Composite International
iagnostic Interview (CIDI) (15), a fully structured interview.
ranslation and back translation followed standard WHO proce-
ures (16).
he Assessment of DSM-IV PTSD
The CIDI PTSD section began with questions about lifetime
ccurrence of 27 PTEs (Table 2). An additional open-ended
uestion then asked about any other traumatic event. Positive
esponses were recorded verbatim and reviewed by a clinical
ater to confirm PTSD criterion A1. A second open-ended
uestion then attempted to obtain information about qualifying
vents that respondents did not report because of embarrass-
ent. Wording was as follows: “[s]ometimes people have expe-
iences they don’t want to talk about in interviews. I won’t ask
ou to describe anything like this, but without telling me what it
as, did you ever have a traumatic event that you did not report
o me because you did not want to talk about it?”
able 2. The Potentially Traumatic Experiences Assessed in the World
ental Health Surveys
I. Experiences Involving Interpersonal Violence
1. Combat experience (military or nonmilitary) in a war or sectarian
violence (e.g., political, religious, or ethnic conflicts)
2. Relief worker or peacemaker in war zone or region of sectarian
violence
3. Civilian in a war zone
4. Civilian in a region of sectarian violence
5. Displaced refugee from a war zone or a region of sectarian
violence
6. Kidnapped or held captive
7. Beaten up as a child by a caregiver
8. Beaten up by a spouse or romantic partner
9. Beaten up by someone else
10. Mugged or threatened with a weapon
11. Raped
12. Sexually assaulted or molested
13. Stalked
II. Other Threats to the Physical Integrity of the Respondent
14. Natural disaster (e.g., flood, hurricane, earthquake)
15. Life-threatening automobile accident
16. Other life-threatening accident
17. Toxic chemical exposure
18. Other exposure to a made disaster (e.g., fire, explosion at a place
of work)
19. Other life-threatening illness or injury
III. Threats to the Physical Integrity of Others
20. Death of a loved one
21. Life-threatening illness of a loved one
22. Any other trauma experienced by a loved one
23. Witnessed repeated physical fights at home as a child
24. Witnessed any other injury or death
25. Accidentally caused injury or death to someone
26. Purposefully injured, tortured, or killed someone
27. Witnessed atrocities or carnage
V. Open-Ended Questions About Other Potentially Traumatic
Experiences
28. Any other objectively qualifying experiences (respondents are
asked to describe these experiences)
29. Private experiences (respondents are explicitly told in advancethat they will not be asked to describe these experiences)
ww.sobp.org/journalAs we knew from previous research (6,17) that some respon-
dents report too many PTEs to assess PTSD for each one, we
assessed one randomly selected PTE plus the respondent’s
self-nominated worst lifetime PTE. The random event is the focus
of the current report, as appropriate weighting yields a represen-
tative sample of all PTEs. We sought such a sample because the
conventional approach of focusing only on the worst PTE gives
a biased perspective on event exposure and impact (18). How-
ever, we also report results for PTEs that received treatment to
ensure that results apply to clinically relevant PTEs.
The random event was selected by numbering each PTE and
either having the computer select one random number from those
endorsed (in countries that used computer-assisted interviewing) or
assigning a random start value unique to each respondent and
selecting the first endorsed event after that value (in countries that
used paper-and-pencil interviewing). The latter method does not
guarantee equal probability of selection of PTEs, requiring an
additional weight to adjust for differences in probability of selection
as a function of placement in the list. Once the random event type
was selected, a random occurrence of that event was selected when
there were multiple occurrences. We then weighted the data by the
number of unique occurrences of all qualifying PTEs to produce a
weighted dataset in which each PTE is represented in the propor-
tion it occurred in the population. As an indication of PTE distribu-
tion, the mean number of PTE occurrences among respondents
with more than one was 5.8, with a range of 2 to 160 and
interquartile range of 3 to 6.
Criterion A2 was considered met if the respondent endorsed
any of three questions about whether, at the time of the random
PTE, he or she felt 1) terrified or very frightened, 2) helpless, or
3) shocked or horrified. The remaining criteria were then as-
sessed as whether or not A2 was endorsed with questions about
re-experiencing (criterion B), avoidance/numbing (criterion C),
arousal (criterion D), duration (criterion E), and clinically signif-
icant distress impairment (criterion F). A retrospective question
asked respondents how many months or years symptoms contin-
ued. All responses were converted into months (e.g., 5 years  60
months) for analysis of persistence. Blinded clinical reappraisal
interviews with the Structured Clinical Interview for DSM-IV
(SCID) (19) carried out in the United States WMH survey (20)
found an area under the receiver operating characteristic curve of
.69 between PTSD diagnoses based on the CIDI and SCID.
The Assessment of Correlates of PTSD
Other lifetime DSM-IV/CIDI disorders considered were anxi-
ety disorders (panic disorder, phobias, generalized anxiety dis-
order), mood disorders (major depressive disorder, dysthymic
disorder, bipolar I–II disorder), and substance disorders (alcohol
and drug abuse or dependence with abuse). Organic exclusion
rules and diagnostic hierarchy rules were used in making these
diagnoses (15). As described elsewhere (21), blinded SCID
clinical reappraisal interviews (19) in the United States WMH
sample documented generally good CIDI-SCID concordance
(area under the receiver operating characteristic curve) for
diagnoses of anxiety (.73), mood (.93), substance (.86), and any
(.76) disorder. Lifetime suicidal ideation was assessed with a
single question that asked respondents if they ever seriously
thought about killing themselves and, if so, their age when this
first occurred.
Analysis Methods
Cross-tabulations examined frequency of individual PTEs,conditional prevalence of DSM-IV PTSD with and without A2,
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E.G. Karam et al. BIOL PSYCHIATRY 2010;68:465–473 469nd co-occurence of criteria B through F. Logistic regression (22)
xamined sociodemographic predictors of PTSD with or without
riterion A2 and interactions of predictors with presence-absence
f A2. Discrete-time survival analysis (23) with person year the
nit of analysis was used to examine association between PTSD
ith and without A2 and persistence, as well as subsequent first
nset of other DSM-IV/CIDI disorders and suicidal ideation. All
arameters were estimated using the Taylor series method (24) in
he SUDAAN software system (Research Triangle Institute, Re-
earch Triangle Park, North Carolina) (25). Significance was
valuated using .05 level two-sided Wald 2 tests.
esults
revalence of DSM-IV PTSD Criteria A1 and A2
Lifetime exposure to PTEs was reported by 67.9% of respon-
ents (72.8% in high-income, 61.7% in upper-middle-income,
nd 63.1% in low-income/lower-middle-income countries). Dis-
ggregated comparisons (detailed results available on request)
ound the higher exposure in high-income countries due largely
o automobile accidents. Weighted mean number of PTEs per
espondent with any was 4.5 (4.7 in high-income, 4.1 in upper-
iddle-income, and 4.6 in low-income/lower-middle-income
ountries) for 305.6 lifetime PTEs for every 100 respondents (i.e.,
7.9%  4.5) and 137,778 PTEs in the full sample.
ther Criteria for DSM-IV PTSD
Approximately one third (37.6%) of weighted PTEs were
eported as meeting A2 (Table 3). This proportion is substantially
ower in high-income than upper-middle-income or low-in-
ome/lower-middle-income countries. Conditional prevalence of
eeting all other DSM-IV requirements for PTSD is dramatically
igher in the presence (9.7%) than absence (.1%) of A2. Condi-
ional prevalence of PTSD given A2 is positively related to
ountry income level. Conditional prevalence of all other re-
uirements for PTSD in the absence of A2 is very low (.0%–.1%)
egardless of country income level.
It is unclear whether these results, which involve retrospec-
ive reporting of A2 in some cases many years after the PTE,
ccurately reflect the way the respondent would have character-
zed their short-term reactions at the time of the PTE. To the
able 3. Percentage of the Representative Sample of Potentially Traumatic
2 and Conditional Prevalence of DSM-IV/Composite International Diagnos
riterion A2
ountry Income
Percentage of PTEs That Had
Criterion A2
% (SD) (n)a
evels
ll 37.6 (.9) (28,490)
High 28.6 (1.1) (17,815)
Upper-middle 52.2 (1.7) (6,962)
Low/lower-middle 49.5 (2.7) (3,713)
PTE, potentially traumatic experience; PTSD, posttraumatic stress disord
aThe n=s reported here are unweighted denominators of the number of
ased. For example, aweighted 36.7%of the 28,490 PTEs reported (an obser
iagnostic InterviewA2 criterion,while aweighted 9.7%of these 11,121 PTE
nterview criteria for posttraumatic stress disorder. The ratio of the num
28,490/52,949  53.8%) is lower than the weighted 67.9% of responden
omewhat underrepresented in the samples.extent that they do, though, the results would mean that an
assessment of A2 shortly after PTE occurrence might help predict
subsequent PTSD. Indeed, if we compare the proportion of all
random PTEs that meet full criteria for PTSD (by multiplying
conditional prevalence of PTSD given A2 by the proportion of all
PTEs with A2, both reported in Table 3) with the additional
proportion that would meet criteria for PTSD if A2 was no longer
required for diagnosis (by multiplying conditional prevalence of
PTSD without A2 by the proportion of all PTEs without A2, both
reported in Table 3), we find that the retrospective results suggest
that only 1.4% of respondents who met all other requirements for
PTSD would be missed if follow-up assessment was carried out
only among people with A2. This estimated proportion is very
similar in high-income, upper-middle-income, and low-income/
lower-middle-income countries (.6%–2.0%). More detailed exam-
ination (available on request) found no country or PTE for which
the proportion of respondents meeting all other requirements
who would be missed by focusing on A2-positives is significantly
more than 2%. That is, the upper end of the 95% confidence
interval of these prevalence estimates never exceeded 2%.
Furthermore, additional analyses (detailed results available on
request) found that the percentage is even smaller (1.1%) among
PTEs for which professional treatment was sought, demonstrat-
ing that the low percentage holds for the most clinically relevant
PTEs.
As noted in the introduction, one other rationale for including
A2 in DSM-IV was that it provided a quick rule-out for noncases.
As it happens, though, our results suggest this is not true.
Exclusion of PTEs that failed A2 would reduce by an estimated
62.4% (i.e., 100%  the 37.6% of PTEs that met criterion A2) the
number who would have to be further assessed and would miss
only 1.4% who met all other criteria. Although this seems like a
very effective screening rule, higher conditional prevalence of A2
than other DSM-IV criteria means the proportion of noncases
ruled out by A2 would be considerably lower than those ruled
out by assessing any other DSM-IV criterion. For example,
assessing criterion F (clinically significant distress-impairment)
would exclude 90.4% of noncases compared with 62.4% by
assessing A2.
riences Assessed in the World Mental Health Sample That Had Criterion
terview Posttraumatic Stress Disorder in the Presence Versus Absence of
ditional Prevalence of PTSD in
he Presence of Criterion A2
Conditional Prevalence of All
Other Requirements for a
Diagnosis of PTSD in the
Absence of Criterion A2
(SD) (n)a % (SD) (n)a
(.7) (11,121) .1 (.0) (17,369)
(1.2) (6,341) .1 (.0) (11,474)
(.8) (3,103) .1 (.1) (3,859)
(1.0) (1,677) .0 (.0) (2,036)
ntially traumatic experiences (PTEs) on which the prevalence estimates are
1,121 PTEs) were classified asmeeting theDSM-IV/Composite International
e classified asmeeting all otherDSM-IV/Composite International Diagnostic
of respondents who reported at least one PTE to the total sample size
o reported a PTE because people with high rates of PTE exposure wereExpe
tic In
Con
t
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15.0
6.3
3.8
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whe Clinical Significance of PTSDWithout A2
The above results show that removal of A2 from the criterion
et would have very little effect on the number of people who
ualify for a diagnosis of PTSD based on randomly selected PTEs
n the WMH sample. The PTSD prevalence based on randomly
elected PTEs would increase only from 3.64% to 3.69% (about a
% increase on the base of 3.64%) if we excluded A2, adding
nly 21 cases classified as meeting full criteria for PTSD out of the
8,490 cases in the weighted sample of randomly selected PTEs
.07% of all such PTEs). In considering whether such a modest
ifference justifies inclusion of A2 in the DSM-IV criterion set, it
s relevant to know whether the few otherwise qualifying cases
re so distinct in terms of low clinical significance that they need
o be excluded. We addressed this question by examining
hether PTSD differs in course depending on presence-absence
f A2. No such difference was found. The odds ratio (OR) (95%
onfidence interval in parentheses) of presence-absence of A2
redicting differential persistence of PTSD among cases with
ersus without A2 was insignificant [1.02 (.42–2.47), 21 .0, p
97]. The OR of PTSD without A2 predicting subsequent first
nset of other DSM-IV/CIDI disorders was actually higher,
lthough not significantly so (21  1.0, p  .32), for PTSD
ithout than with A2: 9.9 (2.1–47.1) versus 4.4 (3.2–6.1). The
ame basic pattern holds in predicting subsequent onset of
uicidal ideation with an OR (95% confidence interval) of 3.6
able 4. Logistic Regression Equations Predicting Whether the Potentially
xperiences Assessed in the World Mental Health Sample That Satisfy All Ot
iagnosis of Posttraumatic Stress Disorder
All
OR (95% CI)
ex
Male 5.1a (1.6–16.5)
Female 1.0 –
21 7.4
a
ge at Trauma Exposure
0–9 .5 (.1–3.3)
10–19 .7 (.1–5.0)
20–29 .5 (.1–3.7)
30–39 1.7 (.3–12.0)
40 1.0 –
24 1.9
istory of Prior (to Age of PTE Exposure)
DSM-IV/CIDI Disorders
Yes .2a (.1–1.0)
No 1.0 –
21 4.0
a
istory of Prior (to Age of Occurrence of the
Random PTE) PTE Exposure
Yes .8 (.2–2.9)
Number 1.0 –
21 .2
(n) (1,340)b
CI, confidence interval; CIDI, Composite International Diagnostic Intervi
aSignificant at the .05 level, two-sided test.
bThe n=s reported here are the unweighted numbers of potentially tra
nclude all PTEs in the representative sample of PTEs that were judged to m
iagnosis of posttraumatic stress disorder in thepresence or absence of crite
isorder criteria but not criterion A2.
cThe number of observed cases of posttraumatic stress disorder without
olychotomous variable.
ww.sobp.org/journal(2.8–4.7) for PTSD with A2 and 4.4 (.8–24.7) without A2 (21 
.1, p  .83).
CompositionalDifferences BetweenPTSDWith andWithoutA2
We investigated whether the composition of cases of PTSD
differs depending on presence-absence of A2 using logistic
regression where information about age at time of PTE exposure,
sex, history of prior lifetime DSM-IV/CIDI disorders, and history
of prior PTE exposure were used to distinguish PTSD with and
without A2 (Table 4). Men had significantly higher odds than
women of PTSD without than with A2 (5.1). Respondents with a
history of other DSM-IV/CIDI disorders had significantly lower
odds than others of PTSD without than with A2 (.2).
Discussion
This study found that PTEs are commonly occurring, that a
much higher proportion of the randomly selected PTEs meet
criterion A2 than any other DSM-IV PTSD criterion, that condi-
tional prevalence of meeting diagnostic threshold based on other
criteria is significantly higher in the presence than absence of A2,
and that only a small fraction of respondents who meet diagnos-
tic threshold based on other criteria fail to meet A2. The last of
these results means the sample-specific prevalence of PTSD
increased only very slightly when A2 was not required for
atic Experience Met Criterion A2 in the Sample of Potentially Traumatic
riteria for a DSM-IV/Composite International Diagnostic Interview
Country Income Level
High Upper-Middle Low/Lower-Middle
R (95% CI) OR (95% CI) OR (95% CI)
4a (2.1–33.8) .8 (.1–4.9) 12.1a (1.1–129.4)
0 – 1.0 – 1.0 –
9.0a .1 4.2a
8 (.1–6.9) .0 (.0–.3) –c –
9 (.1–9.6) .4 (.0–6.5) – –
6 (.1–6.8) .1 (.0–.9) – –
2 (.1–21.8) 1.0 (.1–13.6) – –
0 – 1.0 – – –
.4 8.9 –c
2 (.0–1.5) .4 (.0–3.4) .3 (.1–1.1)
0 – 1.0 – 1.0 –
2.4 .8 3.1
0 (.2–5.8) .5 (.1–2.4) 1.1 (.1–9.1)
0 – 1.0 – 1.0 –
.0 .9 .0
(981)b (267)b (92)b
R, odds ratio; PTE, potentially traumatic experience.
ic experiences (PTEs) on which the regression equations are based. These
ll other DSM-IV/Composite International Diagnostic Interview criteria for a
2. The outcome iswhether or not the PTEmet all other posttraumatic stress
ion A2 in this subsamplewas too small to estimate the associationwith thisTraum
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E.G. Karam et al. BIOL PSYCHIATRY 2010;68:465–473 471iagnosis. Furthermore, cases meeting all other PTSD criteria do
ot differ in persistence, subsequent suicidal ideation, or second-
ry disorders from PTSD cases. We concluded from these results
hat A2 should be reconceptualized as a risk factor for PTSD
ather than as a diagnostic requirement, as the retrospective data
ndirectly suggest that the occurrence of A2 symptoms shortly
fter the occurrence of the PTE is significantly predictive of
ubsequent PTSD, even though the inclusion of A2 as a require-
ent for diagnosis has little effect on case definition once other
iagnostic requirements are met.
Our finding that a substantial minority of PTEs was reported
s causing intense fear, helplessness, or horror in countries
hroughout the world is consistent with previous studies in a
arrower range of countries (4,6,7,26). It is unclear, though, why
onditional prevalence of A2 is significantly lower in high-
ncome (28.6%) than lower-income (49.5%–52.2%) countries.
his could be due to PTEs in lower-income countries being, on
verage, more extreme (either in terms of characteristics of or
bjective consequences of the events) than in high-income
ountries. Another possibility is that people in low-income
ountries are more likely than those in high-income countries to
e shocked or horrified by the occurrence of a traumatic stress.
e are not aware of any cross-national research that addresses
his second possibility, but it is indirectly inconsistent with
esearch in the United States that documented stronger effects of
ome traumatic events in leading to shock and horror among
iddle class than lower class people due to middle class people
eing more likely to have illusory world views about control and
ustice that are shattered by exposure to traumatic events (27,28).
hy we would find the opposite pattern in cross-national
omparisons is perplexing. Another significant between-country
ifference is that conditional prevalence of PTSD given A2 is
ignificantly higher in high-income (15.0%) than lower-income
3.8%–6.3%) countries. These differences might reflect between-
ountry differences in coping resources that influence emotional
eactions to trauma.
Our finding that conditional prevalence of A2 given A1 far
xceeded conditional prevalence of any other DSM-IV criterion
f PTSD suggests that it would be more efficient to use a criterion
ther than A2 for screening to quickly rule out a diagnosis of
TSD. This is due to the high prevalence of A2 occurring not only
mong people with PTSD but also among people without PTSD.
Our finding that only a small proportion of PTEs without A2
ere associated with all other DSM-IV requirements for PTSD is
onsistent with most (1,4,6,7), but not all (8), previous studies.
his means that removal of A2 from the criterion set would lead
o only a modest increase in the number of people diagnosed
ith PTSD. Furthermore, the small number of cases of PTSD
ithout A2 in the WMH series had equal PTSD persistence and
qually elevated risk of temporally secondary mental disorders
nd suicidal ideation as cases with A2. This means that the small
umber of otherwise qualifying cases excluded by A2 should not
e excluded. This conclusion is reinforced by evidence from
ther research that A2 is often absent in patients from high-risk
ccupations (e.g., military, police, fire fighters) who otherwise
eet criteria for PTSD associated with traumatic events that
ccurred in the context of their occupation (29), as well as
mong those who were amnesic (8).
An especially intriguing finding was that conditional risk of
TSD without versus with A2 was significantly higher among
espondents with than without a history of other DSM-IV/CIDI
isorders. This might have been caused by prior psychopathol-
gy creating stronger vulnerability for PTSD associated with lesssevere than more severe PTEs, where the occurrence of A2
symptoms is a marker of PTE severity. This possibility is consis-
tent with the general diathesis-stress model of anxiety disorders
(30). This model suggests that increased vulnerability to stress (as
indicated here by history of psychopathology) reduces the
amount of stress needed to promote onset of a stress-related
anxiety disorder, whereas vulnerability factors become less im-
portant at high levels of stress exposure due to resistance
resources becoming overwhelmed when stress is extreme.
As noted in the introduction, one original rationale for
including A2 in DSM-IV was that expansion of criterion A1 in
DSM-IV might lead to an inappropriate broadening of the
definition of PTSD unless a new subjective A2 requirement was
used to delimit the range of qualifying traumas (2,4,5). As it turns
out, the WMH results show that A2 did not have this desired
effect. A somewhat different version of this argument is that the
definition of a traumatic experience needs to include a short-term
subjective component to focus clinical attention shortly after the
time of trauma exposure on the subset of PTEs most likely to lead
to the other PTSD criteria. This view might make good sense
when it comes to predicting subsequent onset of PTSD from
information about short-term emotional reactions to PTEs be-
cause conditional risk of PTSD is low in the absence of A2.
Longitudinal studies have confirmed this predictive association
(31,32). Targeting preventive interventions consequently might
make use of such information (33).
This possible value of the assessment of A2 near the time of
trauma exposure as a predictor of future PTSD should not be
confused with the role of A2 as a requirement for a diagnosis of
PTSD. The distinction is familiar in other areas of medicine. For
example, detection of hypertension is clinically useful as a
predictor of heart attack and usually triggers initiation of preven-
tive interventions. It makes no sense, though, to require a history
of hypertension for a diagnosis of myocardial infarction when a
person has a heart attack. Similarly with PTSD, when a patient
presents for treatment of reactions to a PTE that include DSM-IV
criteria B through F, it would seem perverse to use the patient’s
retrospective report of not experiencing A2 at the time of the PTE
exposure to rule out a diagnosis of PTSD.
Another argument for retaining A2 is that information about
A2 can be valuable in making a differential diagnosis between
PTSD and other syndromes, such as comorbid reactive depres-
sion with phobia, when a patient presents with a mixture of
depression and anxiety related to a PTE. The question of whether
to make a diagnosis of PTSD if the patient’s current symptoms
meet PTSD criteria B through F even if the patient fails to recall
A2 emotional reactions at the time of the trauma then has to be
considered. The data presented here are unable to address this
issue. Research to investigate this issue would be an important
addition to other studies that have been called for to refine our
understanding of differential treatment response in PTSD (34),
especially if a differential treatment response could be found
based on retrospective assessment of A2.
These findings should be interpreted in the context of several
important limitations. First, WMH interviews were conducted by
lay interviewers rather than clinicians. This is an especially
important issue for the evaluation of retrospective reports of
complex emotional responses like those involved in A2. Second,
the clinical validation of PTSD was restricted to the United States.
Concordance of the CIDI diagnoses with clinical diagnoses may
not be as good in some other countries. Third, PTSD was
assessed in a lifetime framework, which introduces the possibil-
ity of recall bias. Fourth, results may not generalize to PTEs that
www.sobp.org/journal
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were not considered in the CIDI assessment or that were so
arely reported that few such PTEs were represented in our
andomly selected series.
The third limitation is especially important in light of the high
roportion of respondents with other requirements for a diag-
osis of PTSD who retrospectively reported that they met A2 at
he time of PTE exposure (98.6%). This proportion exceeds the
omparable proportion found in the one prospective general
opulation study that examined this issue (89%) (26), raising the
ossibility that A2 is recalled as being more prevalent than it
ctually was. If this is the case, then the small proportion of cases
f PTSD estimated to be excluded from a diagnosis by the A2
equirement may be underestimated. This possibility has to be
onsidered in the context of the fact that some investigators have
alled for A2 to be broadened beyond the focus on fear,
elplessness, and horror to include other strong emotions some-
imes associated with PTSD, including anger, shame, grief, and
xtreme emotional blunting (i.e., shock, dissociation) (26,35,36).
f A2 is broadened in these ways, then it is easy to imagine that
irtually 100% of the people who meet other requirements for
TSD would also meet the broadened definition of A2. This
ould make A2 completely redundant with the other criteria,
hich would argue even more forcefully than the results re-
orted here that A2 should be considered a risk factor rather than
diagnostic criterion for PTSD.
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